Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

Contributed by: Business Wire

Logo

Images

Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors. (Graphic: Business Wire)

Business Wire embedded0

Tags

Oncology

Health

Genetics

Research

Science

Pharmaceutical

Biotechnology

Acepodia, Bispecific Antibody, Dual-Payload ADCs

More Like This

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences